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A b s t r a c t
the authors report on the possibilities of the clinical use of tau protein, beta amyloid, and cystatin 
C as new markers in the diagnostics of neurodegenerative diseases (ND). In this study the levels of 
tau protein, beta amyloid, and cystatin C in the diagnostics of some of the above-mentioned diseases 
were assessed. We found statistically significantly increased levels of tau protein in 60.3 % of patients 
with ND (diagnosis (dg.) 1+2), and in 92 % of patients with Alzheimer’s dementia (AD, dg. 2). With 
decreased levels of beta amyloid, the Mann-Whitney test showed statistically significant differences be-
tween ND and other diagnostic groups, but using a chi-square test there were no statistically significant 
differences between both groups. For the tau protein/beta amyloid index we found increased levels 
in 87.5 % patients with AD (dg. 2) using a chi-square test and also statistically significant differences 
compared to groups with non-degenerative diseases. the levels of cystatin C in the sera were decreased 
in the ND group statistically significantly compared to inflammatory diseases of the CNS. there was 
no statistically significant difference in cystatin C cerebrospinal fluid (CSF) levels for each diagnostic 
group. We found increased levels of the index of cystatin C (CSF C/serum C) in the group with ND, 
especially with dg. 2, which is statistically significant for groups with non-degenerative diseases. With 
tau protein our results satisfactorily prove a claim of this marker on its possible use in the diagnosis of 
AD, in the case of beta amyloid the result is at least questionable. the existence of decreased cystatin 
C levels in the sera and CSF in patients with ND presumed in earlier studies was not sufficiently con-
firmed on the basis of our study. 
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INtRODuCtION
At present, many authors turn their interest to new possibilities in the diagno-
sis of neurodegenerative diseases (ND). Support for the diagnosis of Alzheimer’s 
dementia (AD) is now provided by cerebrospinal fluid assessment for the levels 
of beta amyloid and tau protein by the methods of ElISA and fluorescence cor-
relation spectroscopy (FCS). Beta amyloid protein is a component of the amyloid 
plaque accumulating in the AD brain. tau protein occurs in the cytoskeleton of 60
CNS neurons, where it stabilises the axonal system; there are low concentrations of 
tau protein in the serum and CSF of healthy individuals. Among other markers that 
can contribute to the diagnosis of ND, we can recently count cystatin C. It is an 
amyloid protein that occurs together with beta amyloid in the walls of arterioles in 
patients with AD. It is an inhibitor of cysteine protease, relatively stable in circula-
tion, and is also known for its clinical utility as an indicator of glomerular filtration 
(gF) (1); cystatin C concentration is considered an excellent correlate of gF levels 
because, in contrast to creatinine and the clearance of endogenous creatinine, it is 
not affected by food, extra-glomerular secretion, the accuracy of urine collection, 
and analytical interferences (2). Cystatin C is usually assessed in the biological 
material by three techniques: the advantage of the ElISA method lies in the possi-
bility of measuring low concentrations but there is no possibility of making a statim 
assessment. Statim testing is possible by nephelometry and turbidimetry, which in 
turn offer no possibility of low concentration measurement. turbidimetry suffers 
the disadvantages of small robustness and low calibration stability. Nephelometry 
is currently the best method for cystatin C measurement. 
In a subset of AD patients, a polymorphism of cystatin C gene (polymorphism 
of A gene for cystatin C is joined to higher risk of AD) and a decreased level of 
cystatin C in the serum were found (3, 4). Cystatin C also participates in the neu-
ronal degenerative as well as reparative processes, it probably inhibits the activity 
of cathepsin l in astrocytes (which together with cathepsin S belongs to the key 
components of the immune potential of astrocytes and microglia) (5). It seems that 
patients with AD have very low concentrations of cystatin C in CSF and sera (cysta-
tin C is accumulated in reactive astrocytes before amyloid formation), and that the 
disease is manifested by congenital haemorrhage and amyloidosis (6). 
the biochemical markers of ND may contribute to diagnostics (tau protein, 
phosphorylated on serine 199 in CSF) and can be used to monitor treatment ef-
fects (cystatin C in CSF). In the case of AD, first the investigated use of tau protein 
and beta amyloid was to aid in the diagnosis of the disease. In patients with AD, de-
creased levels of beta amyloid and increased levels of tau protein were found. their 
ratio – the tau/beta index – is usually increased and has an almost absolute sensitivity,   
high specificity, and also a high negative predictive value in the AD diagnosis.
the assessment of these markers can also contribute to the differential diagnosis 
of vascular dementia but also to distinguishing other forms of primary degenerative 
dementia, such as frontotemporal dementia. In the study of Hulstaert et al. (7), tau 
protein and beta amyloid CSF levels were examined in a set of 413 patients. In the 
subgroup of patients with AD (n=150), a significant increase of tau protein against 
normal levels was reported. In other groups (and also in healthy volunteers), such as 
patients with difficulties without pathological processes in the brain, patients with 
other neurological difficulties and patients with the non-AD type of dementia, there 
were no reported increases of tau protein. On the contrary, a substantial decrease 61
of beta amyloid was described in patients with AD compared to the other groups. 
According to these studies, both compounds are acceptable markers for early diag-
nosis of AD. 
Assessment of tau protein and beta amyloid together demonstrated a predictive 
value for over 90 % for AD diagnosis and according to some studies it can also help 
in differential diagnosis of Pick dementia (FtD) because CSF tau protein levels in 
FtD patients are higher than in the control group but lower than in the AD group, 
whereas CSF beta amyloid levels are lower in FtD when compared to the control 
group but higher than in the AD group (8). A reduction of cystatin C levels was ob-
served in patients with bacterial meningitis (9). According to some authors, cystatin 
C is involved in neurodegenerative and repair processes after ischaemic and me-
chanical injuries (10, 11, 12). Abnormally low cystatin C levels were described in the 
Icelandic variant of hereditary cerebral haemorrhage with amyloidosis (HCHWA), 
the hereditary form of cerebral amyloid angiopathy (CAA), and in progressive de-
mentia (13). 
In our prospective, bicentric, hospital-based study which has been realised at 
the Department of Neurology, university Hospital in Olomouc, and in Hospital 
Šternberk, we studied the significance of tau protein, beta amyloid and cystatin C 
levels in the diagnostics of some of the above-mentioned diseases and we tried to 
evaluate its contribution to differential diagnostics.
MAtERIAl AND MEtHODS
A set of patients (n = 434, 212 males and 222 females, age 5–92, mean 62 + 14, 73) at the Depart-
ment of Neurology, university Hospital in Olomouc and Hospital Šternberk was divided into 9 sub-
groups to compare neurodegenerative diseases (groups 1+2) with the other diagnostics groups (groups 
3–9): 1 – neurodegenerative diseases (m. Parkinson, spinocerebellar ataxia, heredodegenerative neu-
ropathy, n = 43), 2 – Alzheimer’s dementia (AD, n = 26), 3 – serous inflammation of CNS (n = 33), 
4 – bacterial inflammation of CNS (n = 4), 5 – multiple sclerosis (MS, n = 71), 6 – demyelinisation 
neuropathy (AIDP = Acute Inflammatory Demyelinating Polyneuropathy, CIDP = Chronic Inflamma-
tory Demyelinating Polyneuropathy), n = 15), 7 – ischaemic affection of CNS (n = 41), 8 – haemor-
rhagic stroke (n = 5), 9 – other diagnoses without CNS affection (n = 196). 
the CSF was collected in all patients on the basis of informed consent. Basic morphological 
and biochemical assessment (specific proteins, haematoencephalic barrier integrity test, Reiber cal-
culation) was performed. the ElISA method was used for the assessment of the particular markers: 
tau protein (ElISA, Biosource, uk), beta amyloid (ElISA, Innogenetics, Belgium), and cystatin C 
(ElISA, Biovendor, Brno, Czech Republic). the whole study was conducted in accordance with the 
Helsinki Declaration of 1975 (as revised in 1983) and was approved by the local ethics committee of 
our hospital.
the normal CSF reference values were: 0–210 ng/l for tau protein, 400–1200 pg/l for beta amyloid, 
0–0.5 for tau/beta index, 3–12.5 mg/l for cystatin C. For serum cystatin C, the normal reference values 
were 0.63–1.44 mg/l.62
RESultS
A basic description of tau protein, beta amyloid, and cystatin C values in groups 
of neurodegenerative and non-degenerative diseases is reported in Table 1. 
We found statistically significantly increased levels of tau protein in 60.3 % of 
patients with ND (dg. 1+2) and in 92 % of patients with AD (dg. 2) by the chi-square 
test compared to groups 5, 7, 8 (Fig. 1). 
Table 1
Basic description of cystatin C, tau protein, and beta amyloid for both groups of neurodegenerative 
and non-degenerative diseases
In the case of beta amyloid, we found only a borderline trend (compared to other 
groups) to its decrease, in both groups with ND normal levels of beta amyloid were 
usually found. In the group of AD patients it was only 31.3 % but, with regard to the 
other diagnosis, it was the highest number. the Mann-Whitney test showed statisti-
cally significant differences between the levels of beta amyloid (Fig. 2) in subgroups 
1+2 and subgroups 3–9, but in the chí-square test there were no statistically signifi-
cant differences between both groups. 
For the tau protein/beta amyloid index, we found increased levels in 44.2 % 
patients with ND (dg. 1+2). In patients with AD (dg. 2), it was 87.5 % patients – 
a statistically significant difference (chi-square test) compared to groups 3, 4, 5, 9 
(Fig. 3).
the levels of cystatin C in the serum were decreased in the group with ND   
(dg. 1, 2), which is a statistically significant difference compared to subgroup 3. Higher 
levels of cystatin C were found in subgroup 8, which differs statistically significantly 
from group 9. there was no statistically significant difference in cystatin C CSF lev-
els for each diagnostic group. the highest number of decreased levels is shown by the 63
group with inflammatory diseases of CNS (dg. 3, 4). We found increased levels of 
the cystatin C index (CSF C/serum C) in the group with ND, especially with dg. 2,   
which is statistically significant for dg. 3, 6, 7, and 9 (Fig. 4). 
Fig. 1
tau protein in neurodegenerative and non-degenerative diseases
Fig. 2
Beta amyloid in neurodegenerative and non-degenerative diseases64
Fig. 3
tau protein/beta amyloid index in neurodegenerative and non-degenerative diseases
Fig. 4
Cystatin C index in neurodegenerative and non-degenerative diseases65
DISCuSSION
Our findings of increased tau protein levels in CSF in patients with ND (dg. 1, 2)   
confirmed and replicated early literary data (7,14,15). though this is only a border-
line trend, we can basically confirm the published hypothesis about the decrease of 
CSF beta amyloid in AD patients (16).
According to the study of Kálman (17), there were no statistically significant 
differences between the cystatin C levels in the serum and CSF in patients with 
AD and ischaemic vascular dementia compared to the other groups of patients. 
Shimode (18) came to similar conclusions. In contrast, other studies (3,4) report de-
creased levels of cystatin C in the serum of patients with AD. In our study, 42.9 % of 
AD patients had decreased serum levels of cystatin C, which is the highest number 
from all diagnostic groups, but still the remaining 57.1 % of AD patients had normal 
levels. Cystatin C levels in the CSF of AD patients showed normal levels in 70.6 %;   
therefore we cannot confirm the suggestion of its decreased levels in this type of 
disease. 
Decreased levels of cystatin C were described in patients with local and systemic 
inflammatory diseases (19). In our study, no cases of decreased levels of cystatin C 
were detected in the group of patients with serous inflammatory diseases of CNS 
(dg. 3, 4); on the contrary, this group included the highest percentage (16.7 %) of 
increased serum levels of cystatin C compared to the other diagnostic groups.
According to the study of Nagai (20), a significant decrease of cystatin C was 
observed in patients with the guillain-Barré syndrome, chronic inflammatory demy-
elinisation polyneuropathy (CIDP) and RS compared to the control group. the lev-
els of cystatin C may correlate with the high values of cathepsin B that are described 
in patients with these diseases. In our study, these groups manifested normal levels 
(in 100 % in dg. 6). 
CONCluSIONS
Our study confirms the previously observed results only partially – in the case 
of CSF tau protein, our data strongly support a claim of this marker for its possible 
use in the diagnosis of AD, whereas in the case of CSF beta amyloid, the result is 
at least questionable. the presence of decreased cystatin C levels in the serum and 
CSF in patients with ND suggested in earlier studies was not convincingly con-
firmed in our study.
A c k n o w l e d g e m e n t s 
this project was supported by the IgA MH CR grant No. NF7480 – 3/2003.66
Mareš J., Herzig R., Stejskal D., Vavroušková J., Hluštík P., Urbánek K., Vránová H., Zapletalová J.,  
Pidrman V., Kaňovský P.
VYuŽItÍ NOVÝCH MARkERŮ V DIAgNOStICE  
NEuRODEgENERAtIVNÍCH ONEMOCNĚNÍ
S o u h r n
Autoři referují o možnostech klinického využití tau proteinu, beta amyloidu a cystatinu C jako 
nových markerů v diagnostice neurodegenerativních onemocnění (ND). V této studii byly porovnány 
hodnoty těchto ukazatelů u ND a dalších neurologických onemocnění. Byly nalezeny statisticky 
signifikantně zvýšené hodnoty tau proteinu u pacientů s ND – 60.3% u pacientů s Alzheimerovou de-
mencí (AD) a jinými ND, přičemž u pacientů s AD byly hodnoty zvýšeny v 92%. u snížených hodnot 
beta amyloidu byly podle Mann-Whitney testu prokázány statisticky signifikantní rozdíly mezi skupi-
nou pacientů s ND a pacientů s jiným neurologickým onemocněním, avšak chí-kvadrát test tyto rozdíly 
neprokázal. Pro index tau protein/beta amyloid byly nalezeny zvýšené hladiny u 87.5% pacientů s AD, 
chí-kvadrát test prokázal statisticky signifikantní  rozdíl v porovnání se skupinou jiných neurologick-
ých onemocnění. Hodnoty cystatinu C v séru byly sníženy ve skupině s ND – statisticky signifikantně 
v porovnání  se  zánětlivými  onemocněními  CNS.  Nebyly  zjištěny  statisticky  signifikantní  rozdíly   
u cystatinu C v mozkomíšním moku (CSF). zvýšené hodnoty indexu cystatinu C (CSF C/serum C) 
byly nalezeny u pacientů s ND, zvláště pak u skupiny s AD, která se statisticky signifikantně lišila od 
skupiny s jinými neurologickými onemocněními.  V případě tau proteinu naše výsledky uspokojivě 
podporují teorii o tau proteinu jako diagnostickém markeru AD, v případě beta amyloidu jsou výsled-
ky přinejmenším diskutabilní. Existence snížených hodnot cystatinu C v séru a CSF u pacientů s ND, 
které prokázaly některé dřívější studie, nemůžeme na základě našich výsledků dostatečně potvrdit.
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